Abstract
Excessive cellular proliferation is a major contributor to the pathological changes associated with the secondary complications of diabetes. In particular, hyperglycemia (HG)-induced growth of vascular smooth muscle cells (VSMC) and glomerular mesangial cells (GMC) are characteristic features of the cardiovascular and renal complications of diabetes. VSMC and GMC respond to traditional growth factors, however in diabetes this occurs in the context of an environment, enriched in circulating vasoactive mediators and HG. For example, signaling via the angiotensin II (Ang II) pathway has been implicated in the pathogenesis of diabetic vascular disease. Recent findings indicate that HG and Ang II activate intracellular processes, including the polyol pathway and the generation of reactive oxygen species. These pathways activate the JAK (janus kinase)/STAT (signal transducers and activators of transcription) signaling cascades in both VSMC and GMC. Activation of the latter signaling cascade can stimulate excessive proliferation and growth of these cells, contributing to the accelerated atherosclerosis and nephropathy seen in the diabetic state. This review focuses on key factors in the diabetic microenvironment, in particular the interplay between HG, accumulation of advanced glycation end products and Ang II mediated signaling events both in vitro and in vivo.
Keywords: angiotensin II, jak, hyperglycemia, vascular smooth muscle cells, stat, glomerular mesangial cells
Current Diabetes Reviews
Title: Angiotensin II-Induced Signaling Pathways in Diabetes
Volume: 1 Issue: 2
Author(s): Mario B. Marrero, David Fulton, David Stepp and David M. Stern
Affiliation:
Keywords: angiotensin II, jak, hyperglycemia, vascular smooth muscle cells, stat, glomerular mesangial cells
Abstract: Excessive cellular proliferation is a major contributor to the pathological changes associated with the secondary complications of diabetes. In particular, hyperglycemia (HG)-induced growth of vascular smooth muscle cells (VSMC) and glomerular mesangial cells (GMC) are characteristic features of the cardiovascular and renal complications of diabetes. VSMC and GMC respond to traditional growth factors, however in diabetes this occurs in the context of an environment, enriched in circulating vasoactive mediators and HG. For example, signaling via the angiotensin II (Ang II) pathway has been implicated in the pathogenesis of diabetic vascular disease. Recent findings indicate that HG and Ang II activate intracellular processes, including the polyol pathway and the generation of reactive oxygen species. These pathways activate the JAK (janus kinase)/STAT (signal transducers and activators of transcription) signaling cascades in both VSMC and GMC. Activation of the latter signaling cascade can stimulate excessive proliferation and growth of these cells, contributing to the accelerated atherosclerosis and nephropathy seen in the diabetic state. This review focuses on key factors in the diabetic microenvironment, in particular the interplay between HG, accumulation of advanced glycation end products and Ang II mediated signaling events both in vitro and in vivo.
Export Options
About this article
Cite this article as:
Marrero B. Mario, Fulton David, Stepp David and Stern M. David, Angiotensin II-Induced Signaling Pathways in Diabetes, Current Diabetes Reviews 2005; 1 (2) . https://dx.doi.org/10.2174/1573399054022802
DOI https://dx.doi.org/10.2174/1573399054022802 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mast Cell Tryptase β as a Target in Allergic Inflammation: An Evolving Story
Current Pharmaceutical Design 5-HT7 Receptors
Current Drug Targets - CNS & Neurological Disorders Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases
Current Pharmaceutical Design Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes
Current Drug Targets Sepsis, Coagulation and Anticoagulants
Endocrine, Metabolic & Immune Disorders - Drug Targets Circulatory Estrogen Level Protects Against Breast Cancer in Obese Women
Recent Patents on Anti-Cancer Drug Discovery C6-Ceramide-Coated Catheters Promote Re-Endothelialization of Stretch- Injured Arteries
Vascular Disease Prevention (Discontinued) Consequences of Elevated Homocysteine During Embryonic Development and Possible Modes of Action
Current Pharmaceutical Design Genetic Determinants of HDL Metabolism
Current Medicinal Chemistry Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology Empowering Translational Research in Fetal Growth Restriction: Sheep and Swine Animal Models
Current Pharmaceutical Biotechnology Why is the Incidence of Type 1 Diabetes Increasing?
Current Diabetes Reviews Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design A Metabolomic Study Reveals Novel Plasma Lyso-Gb3 Analogs As Fabry Disease Biomarkers
Current Medicinal Chemistry QSAR Studies of PTP1B Inhibitors: Recent Advances and Perspectives
Current Medicinal Chemistry Gender Differences in Aminoglycoside Induced Nephrotoxicity: A Prospective, Hospital - Based Study
Current Clinical Pharmacology Arecoline Increases the Production of Nitric Oxide and Post-Translational S-Nitrosoproteome in Endothelial Cells
Current Proteomics Current Drug Nano-targeting Strategies for Improvement in the Diagnosis and Treatment of Prevalent Pathologies such as Cardiovascular and Renal Diseases
Current Drug Targets